Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Atlas international atlas adjuvant tamoxifen longer against shorter breast cancer treatment trial

The ATLAS started in 1995, completed randomisation in 2005 and finished trial treatment in 2010.

Follow-up is still continuing, but in 2013 the main results thus far available were published (Lancet 2013; 381: 805-16), focusing on women with oestrogen receptor positive (ER+) breast cancer who had already had about 5 years of tamoxifen. But, although these women are of particular interest, we do still need to get follow-up, preferably to about 20 years after the original diagnosis, on all women entered into ATLAS. In the 2013 Lancet report of the early ATLAS results, most of the follow-up information related to the periods 5-9 and 10-14 years after diagnosis, with little information yet available about longer-term outcomes (see figures below, which are taken from the 2013 Lancet publication).

atlas graph 

The eventual aim is to assess the effects of 10 years of treatment on 20-year outcome. Further follow-up will consolidate the results in years 10-14 after diagnosis, and will assess the further effects during years 15-19 after diagnosis. It could well be that the added benefit of an extra 5 years of tamoxifen persists and becomes somewhat greater by year 20 than by year 15, but to establish that, we require a few more years of follow-up. In the meantime, the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis of the trials of 10 vs 5 years of tamoxifen will – we anticipate – be published around the end of 2016 (including ECOG, the Scottish trial, NSABP B-14, updated data from ATLAS and the new data from aTTom [the UK counterpart of ATLAS]).

Our team

Related research themes